Outsourcing Pharma

JULY 29, 2021

A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.

52

52

Pharmaceutical Technology

MAY 2, 2023

Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients. The firms did not divulge the terms of the deal. They also used their standard colchicine regimen.

52

52

Pharmaceutical Technology

JULY 18, 2022

A lead product of Quoin, QRX003 is a topical lotion intended to treat Netherton Syndrome. As per the terms of the license and distribution deal, Endo holds the exclusive right, which was also sublicensed to the affiliate of the company, Paladin Labs, to market the product in Canada on receiving regulatory approvals.

64

64

Pharmaceutical Technology

DECEMBER 5, 2022

According to the deal, Incyte is entitled to receive an upfront payment from CMS, which will also make further potential payments on meeting development, regulatory and commercial milestones. Ruxolitinib cream is the first topical inhibitor of JAK to obtain approval in the US.

52

52

pharmaphorum

NOVEMBER 2, 2021

Swiss group Novartis has swooped in with a backloaded option deal that includes $24 million upfront in cash and equity – plus up to $1.3 The approach has become a hot topic in biopharma with a string of big ticket partnerships over the last couple of years, including a $2.4 Others include a $1.6

98

98

Pharmaceutical Business Review

MARCH 5, 2024

This platform enhances the dissolution and bioavailability of active pharmaceutical ingredients (APIs), which is crucial for topical, oral, and inhaler drug delivery. As per the deal, Formosa received upfront as well as development and sales-based milestone payments totalling $86m apart from other agreement considerations.

59

59

Pharmaceutical Technology

NOVEMBER 29, 2022

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. Under the deal, Neogene will receive $200m in initial payment at closing, as well as up to $120m in contingent milestones-based and non-contingent payments.

Communication 111

Communication 111

Pharmaceutical Technology

FEBRUARY 16, 2023

The collaboration will combine the Optejet dispensing technology of Eyenovia with the APNT nanoparticle formulation platform of Formosa to develop topical therapeutics. Under the deal, both companies will work together to develop new drugs using APNT formulations in the Optejet dispenser.

59

59

Pharma and Life Sciences Blog

MAY 4, 2023

Managing Costs: Adapting Supply Chains to the Current Economic Environment annmarie@AZglo… Thu, 05/04/2023 - 16:57 Are you a supply chain or procurement leader looking for strategies to deal with rising costs amidst the uncertain economic landscape?

40

40

Pharmaceutical Technology

FEBRUARY 8, 2023

Under the deal, AGC Biologics will be responsible for manufacturing the cell therapy lentivirus-based product for the ongoing clinical programmes of Genenta Science. Genenta stated that the services offered under the existing deal are in addition to those offered under the agreement signed with AGC Biologics.

Immunity 52

Immunity Immunization 52

pharmaphorum

AUGUST 17, 2020

The French pharma said it will pay $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by both boards of directors. Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline.

Immunity 124

Immunity Immunization Diabetes 124

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. The Sartorius-Polyplus deal is expected to close in Q3 2023. Topic sponsors are not involved in the creation of editorial content.

98

98

Pharmaceutical Technology

JULY 5, 2022

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of TeneoTwo as well as its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.27bn to bolster the haematological cancer pipeline. As per the deal, AstraZeneca will make an upfront payment of $100m on the closing of the transaction.

Immunity 59

Immunity Immunization 59

Pharmaceutical Technology

DECEMBER 8, 2022

Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., Free Whitepaper.

Communication 122

Communication Immunity Immunization Hospitals 122

Pharmaceutical Technology

JULY 12, 2022

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. Topic sponsors are not involved in the creation of editorial content. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Diabetes 110

Diabetes 110

Eye on FDA

AUGUST 17, 2022

Not long ago, a retrospective look that compared the ratio and trend of COVID versus non-COVID related news out of FDA suggested that not only was COVID becoming less of a topic for the agency, but also presented the possibility that there was increasing room for other topics. Soon, we may have a new dominating topic in Monkeypox.

Communication 75

Communication Labelling 75

Pharmaceutical Technology

APRIL 26, 2023

The new deal excludes oncology and other therapeutic areas outside the scope of genetic disease. MiNA will receive an upfront payment and future royalties should BioMarin exercise options from the deal. Financial details of the deal were not divulged. Topic sponsors are not involved in the creation of editorial content.

52

52

Pharmaceutical Technology

SEPTEMBER 22, 2022

Sesen Bio has signed a definitive merger agreement to combine its business with Carisma Therapeutics and create a clinical-stage biotechnology firm in an all-stock deal. . On closing of the deal, the merged company will be called Carisma Therapeutics, and its headquarters will be located in Philadelphia, Pennsylvania, US.

Immunity 52

Immunity Immunization 52

Pharmaceutical Technology

SEPTEMBER 21, 2022

Rocket Pharmaceuticals has entered a definitive agreement for the acquisition of biotechnology firm Renovacor in an all-stock equity deal worth nearly $53m, or $2.60 Subject to necessary closing conditions and approvals, the deal is anticipated to conclude in the first quarter of next year. for each share.

59

59

Pharmaceutical Technology

OCTOBER 25, 2022

According to the deal, Astellas will acquire 15% of Taysha’s outstanding common stock by making an investment totalling $50m. Topic sponsors are not involved in the creation of editorial content. This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

105

105

pharmaphorum

DECEMBER 21, 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. By far the biggest pharma deal of the year is AstraZeneca’s late-breaking offer to buy Alexion for $39 billion.

Biosimilars 126

Biosimilars Chemotherapy Immunity Immunization 126

Pharmaceutical Technology

AUGUST 1, 2022

Under this deal, SII will gain access to the technology platform of GreenLight for developing, producing and marketing up to three messenger RNA products in markets with a combined population of over five billion. Topic sponsors are not involved in the creation of editorial content.

Vaccines 98

Vaccines Immunity Immunization 98

Pharmaceutical Technology

AUGUST 26, 2022

Under the 30-year deal, ElevateBio will set up its next BaseCamp process development and Good Manufacturing Practice (GMP) manufacturing facility in Pittsburgh. Additionally, the County of Allegheny and the Commonwealth of Pennsylvania contributed incentive grants to ElevateBio for supporting the deal of setting up a biomanufacturing centre.

64

64

Pharmaceutical Technology

MARCH 28, 2023

Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. Topic sponsors are not involved in the creation of editorial content.

Diabetes 94

Diabetes Communication 94

Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Topic sponsors are not involved in the creation of editorial content.

Immunity 98

Immunity Immunization 98

Pharmaceutical Technology

FEBRUARY 16, 2023

The preclinical research deal will combine the MicroOrganoSphere (MOS) platform of Xilis with the expertise of MD Anderson for advancing new therapies development and cancer research. Under the deal, MD Anderson and Xilis aim to advance the development of drug and discovery projects using the MOS technology.

Drug Development 96

Drug Development Communication 96

Pharmaceutical Technology

MARCH 30, 2023

The topical and oral form of the compound is intended to treat glaucoma and dry age-related macular degeneration (AMD), as well as other ophthalmic indications with high unmet medical need, in Africa, the Middle East, the Americas and Europe. It is currently ready to enter Phase II/III clinical trials.

Compounding 52

Compounding 52

Pharmaceutical Technology

AUGUST 1, 2022

The US Department of Health and Human Services, and Administration for Strategic Preparedness and Response (ASPR) and others are supporting the deal through federal funds. Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 115

Vaccines 115

pharmaphorum

MAY 25, 2022

Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) and has been approved by the US regulator with a broad label spanning mild, moderate, and severe psoriasis and an unlimited duration of use.

Labelling 52

Labelling Biosimilars 52

Pharmaceutical Technology

JUNE 9, 2023

Astellas Pharma (Astellas) has entered an exclusive licence deal with Kate Therapeutics (KateTx) to develop and commercialise KT430. KateTx will use the proceeds from the financing and licence deal to advance its portfolio of muscle and heart disease programmes, including facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

59

59

pharmaphorum

OCTOBER 18, 2022

Topical therapies like OCS-01 would complement current approaches by adding an option with improved patient comfort, safety, accessibility, cost, and allowing individualised dosing. glaucoma), the OCS-05 proof-of-concept trial in acute optic neuritis. The post Oculis SA and EBAC join to drive ophthalmology innovation appeared first on.

Diabetes 59

Diabetes 59

pharmaphorum

FEBRUARY 7, 2019

Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS.

52

52

pharmaphorum

SEPTEMBER 21, 2020

The new deal adds more than 80,000 questions and answers to the repertoire of the Alexa virtual assistant, which provides information, entertainment and advice to users on voice command via devices such as Amazon’s Echo smart speakers. The post Amazon bolsters Alexa’s health credentials with Sharecare deal appeared first on.

Mayo Clinic 138

Mayo Clinic HIPAA Online Pharmacies 138

Pharmaceutical Technology

DECEMBER 12, 2022

As per the deal, Arcellx is entitled to $225m in upfront payment in cash following closing, as well as an equity investment of $100m from Kite. The deal is anticipated to conclude in the first quarter of next year. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper.

Communication 105

Communication 105

Drug Channels

OCTOBER 15, 2020

Last week, news broke that Prime Therapeutics is expanding its relationship with Cigna’s Express Scripts to include mail and specialty pharmacy dispensing. So far, there's been very little written about this transaction.

Specialty Pharmacies 52

Specialty Pharmacies 52

Pharmaceutical Technology

APRIL 17, 2023

Both firms will explore private investment in public equity (PIPE) funding before concluding the deal, with NKGen’s majority stockholder NKMax backstopping up to $25m cash funded at $10.00 Topic sponsors are not involved in the creation of editorial content.

98

98

Pharmaceutical Technology

OCTOBER 26, 2022

According to the deal, CEPI will make a payment of up to $140m for R&D expenses to the company. Topic sponsors are not involved in the creation of editorial content. The post SK bioscience and CEPI enter mRNA vaccine development deal appeared first on Pharmaceutical Technology.

Vaccines 52

Vaccines 52